The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports

Possible Treatment for CRC Shows Promise

Research Report

(01/25/2022)

New trial results of Exelixis' cabozantinib in colorectal cancer are encouraging for further development of the biopharma's XL902 in the indication, noted an H.C. Wainwright & Co. report.

Tags: Biotechnology / Pharmaceuticals

Bone Cancer Drug Meets Goals, Stocks Rise

Streetwise Reports (01/25/2022)

Shares of Sierra Oncology Inc. traded 48% higher after the company reported that topline data obtained during its Pivotal Phase 3 MOMENTUM Myelofibrosis Study showed that its momelotinib produced statistically significant improvements in anemia and splenic size.

Tags: Biotechnology / Pharmaceuticals

‘Strong Data’ Expected From Todos Medical Data Lock

Contributed Opinion

Vision and Value (01/24/2022)

Todos Medical is set to take on the dominant players in oral antivirals for mild to moderate COVID-19, Pfizer Inc. and Merck & Co. Inc., with "strong data" expected to be released soon for its drug Tollovir.

Tags: Biotechnology / Pharmaceuticals

Fourth COVID-19 Vaccine Shot Shown Less Effective

Research Report

(01/24/2022)

BioNTech aims to develop a COVID-19 vaccine targeting the Omicron variant, noted an H.C. Wainwright & Co. report.

Tags: Biotechnology / Pharmaceuticals

FDA Gives Fast Track Status to Firm for Adrenal Rescue Pen

Research Report

(01/24/2022)

Now with fast track status and positive Phase 1 study results, Antares Pharma plans to advance its ATRS-1902 product candidate into a second trial in Q2/22, noted a Ladenburg Thalmann report.

Tags: Medical DevicesBiotechnology / Pharmaceuticals

First NSCLC Patient Dosed With Trial Therapeutic

Research Report

(01/22/2022)

Two recent Vaccitech events, the MAGE trial initial dosing and the acquisition of Avidea's SNAPvax technology, bode well for its ChAdOx1-MVA platform, noted an H.C. Wainwright & Co. report.

Tags: Biotechnology / Pharmaceuticals

Fund Triples Holding of Drug Repurposing Firm

Streetwise Reports (01/20/2022)

Several events slated to happen this year could boost Algernon Pharmaceuticals' share price, noted an AlphaNorth Partners Fund performance report.

Tags: Biotechnology / Pharmaceuticals

Belgium Firm to Buy Epilepsy-Focused Biopharma Co. for $1.9B

Streetwise Reports (01/19/2022)

Shares of Zogenix Inc. rose by 66% after the company reported it entered into an agreement to be acquired by UCB. S.A. of Belgium for $26.00 per share in cash. The offer includes the potential for an additional $2.00 per share if a specific drug approval milestone is met.

Tags: Biotechnology / Pharmaceuticals

Derm Biopharma Named Top Growth Pick For 2022

Research Report

(01/18/2022)

Journey Medical should increase 2022 and 2023 revenue by at least 30% such that it could turn a profit in 2024, noted a ROTH Capital Partners report.

Tags: Biotechnology / Pharmaceuticals

This Pharmaceutical Company Has a Brilliant Concept

Contributed Opinion

PennyQueen (01/17/2022)

Algernon Pharmaceuticals is a clinical-stage, small biotech that boasts a massive pipeline of lower risk and efficient drugs. Catalysts abound with this genius repurposing company.

Tags: Biotechnology / Pharmaceuticals

Vaccine Maker Doses 1st Patient in Phase 1b Parkinson's Trial

Streetwise Reports (01/12/2022)

Shares of new class synthetic vaccine developer Vaxxinity Inc. traded 23% higher after the company reported it has dosed the first patient in its Phase 1b UB-312 Parkinson's disease study.

Tags: Biotechnology / Pharmaceuticals

Ph1 Trial Results of Dementia Drug Positive

Research Report

(01/12/2022)

Anavex Life Sciences' study of Anavex 3-71 in frontotemporal dementia met primary and secondary safety endpoints, noted a Dawson James Securities report.

Tags: Biotechnology / Pharmaceuticals

Biotech Co. Partners With Life Sciences Firms

Research Report

(01/11/2022)

2seventy entered agreements with Novo Nordisk and Genevant to get an in vivo gene editing treatment for hemophilia A developed, noted a Wedbush report.

Tags: Biotechnology / Pharmaceuticals

Enrollment Done for COVID-19 Drug Trial

Research Report

(01/10/2022)

Part 2 of First Wave BioPharma's RESERVOIR trial of niclosamide to remove the SARS-CoV-2 virus from the GI tract is underway, noted a ROTH Capital Partners report.

Tags: Biotechnology / Pharmaceuticals

2022 to Be Catalyst Rich for Biopharma

Research Report

(01/10/2022)

The potential stock-moving events for Infinity Pharmaceuticals this year include the launch of two clinical trials and readouts from four studies, noted an H.C. Wainwright & Co. report.

Tags: Biotechnology / Pharmaceuticals

Co.'s samRNA Vaccines Protect Better Against COVID Variants

Research Report

(01/07/2022)

Gritstone bio Inc.'s lower-dose samRNA vaccines include a broader immune response to SARS-CoV-2 and may provide better protection against emerging variants. BTIG research has issued a "Buy" rating for Gritstone bio.

Tags: Biotechnology / Pharmaceuticals

AI Driven Drug Firm Partners With Merck

Streetwise Reports (01/07/2022)

Shares of Absci Corp. rose 18% after the company reported it is collaborating with Merck & Co. to create enzymes using its deep-learning Integrated Drug Creation™ platform and Bionic Protein™ technologies.

Tags: Biotechnology / Pharmaceuticals

Co. Partners to Test New Cancer Vaccines

Research Report

(01/06/2022)

Genocea Biosciences Inc. is teaming up with Janssen Biotech to explore the immunogenicity of neoantigens and the role and impact of Inhibigens™ in potential vaccine therapies for cancer. H.C. Wainwright & Co. advised that it currently has a "Buy" rating on Genocea.

Tags: Biotechnology / Pharmaceuticals

Co. Plans to Make 100M Rapid COVID Tests Monthly

Research Report

(01/05/2022)

Biopharmaceutical firm Sorrento Therapeutics Inc. plans to mobilize a fully automated assembly line in San Diego, Calif., capable of producing 6 million rapid antigen detection COVISTIX testing units per month starting in Q1/22.

Tags: Biotechnology / Pharmaceuticals

New Muscular Dystrophy Drug Shows Promise

Streetwise Reports (01/05/2022)

Edgewise Therapeutics shares traded 24% higher after the company reported its EDG-5506 significantly lowered muscle damage biomarkers in adults after just two weeks of dosing in its Becker muscular dystrophy trial.

Tags: Biotechnology / Pharmaceuticals

Chen Lin's Top 6 Investment Ideas

Streetwise Reports (01/05/2022)

In a recent interview with Streetwise Reports, family assets manager and contributing writer, Chen Lin, shared the six (mostly mid-cap) companies that are his top investment picks for 2022.

Tags: GoldBiotechnology / Pharmaceuticals

Lead Cancer Drug Gets Fast Tracked

Streetwise Reports (01/03/2022)

Shares of Genprex Inc. traded 165% higher after the company reported the U.S. FDA has awarded Fast Track Designation for its REQORSA™ Immunogene Therapy for use in combination with Merck & Co.'s Keytruda® for non-small cell lung cancer treatment.

Tags: Biotechnology / Pharmaceuticals

Analyst: Drug a 'Hidden Gem for 2022'

Research Report

(12/31/2021)

Oppenheimer ranks Astria Therapeutics Outperform after learning about its drug for hereditary angioedema, saying "We stay bullish."

Tags: Biotechnology / Pharmaceuticals

Co. Still Compelling After Drug Trial Failure

Research Report

(12/29/2021)

"Arcalyst remains the value driver" for Kiniksa Pharmaceuticals, and "we continue to hold a favorable view of the company," noted a Wedbush report.

Tags: Biotechnology / Pharmaceuticals

Co. Looks To US For Help Fighting Strokes

Streetwise Reports (12/29/2021)

Canadian company Algernon Pharmaceuticals Inc. has applied to uplist to the Nasdaq in hopes of attracting U.S. investors to its mission to repurpose drugs.

Tags: Biotechnology / Pharmaceuticals

Showing Results: 1 to 25 of 119 Next